Last edition
News about "Phase 1/2 clinical trial"
Estrella Doses First Patient in EB103 Dose-Expansion Trial for Relapsed/Refractory B-Cell NHL
Estrella Immunopharma advances its STARLIGHT-1 Phase I/II trial with the first patient dosed in the EB103 dose-expansion cohort, building on promising early efficacy in relapsed/refractory B-cell non-Hodgkin’s lymphoma.
Phase 1/2 Clinical Trial | 28/07/2026 | By News Bureau
Healx Doses First Patient in Phase 1/2 Trial of AI-Discovered Therapy for Relapsed Osteosarcoma
Healx has dosed the first patient in its Phase 1/2 trial of AI-developed investigational therapy HLX-4310, marking a milestone in the development of novel treatments aimed at preventing metastatic recurrence in osteosarcoma and other rare cancers.
Phase 1/2 Clinical Trial | 24/07/2026 | By News Bureau
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib
Revolution Medicines presented phase 1/2 clinical data showing the potential of zoldonrasib combination regimens in patients with RAS G12D metastatic pancreatic cancer at ESMO Gastrointestinal Cancers Congress 2026.
Phase 1/2 Clinical Trial | 04/07/2026 | By News Bureau | 109
AskBio Doses First Participant in Phase 1/2 Trial for Pompe Disease Gene Therapy
AskBio has dosed the first participant in its Phase 1/2 PROGRESS-GT LOPD trial evaluating investigational gene therapy AB-1009 for late-onset Pompe disease, advancing research into potential long-term treatment solutions for the rare genetic disorder.
Phase 1/2 Clinical Trial | 14/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy